Anaesthetics (A61P23)

A   Human necessities(312083)
A61P23                 Anaesthetics(281)
A61P23/02 - Local anaesthetics(150)
Gel including nifedipine and lidocaine hydrochloride (versions), application of gel including nifedipine and idocaine hydrochloride (versions), method for preparation of gel including nifedipine and idocaine hydrochloride, using nanotechnology // 2641570
FIELD: pharmacology.SUBSTANCE: method for gel preparation consists in preparation of two separate solutions and a nifedipine suspension, followed by mixing of the solutions and suspension at a temperature of 20-37°C for 1-9 hours with further filtration and gel preparation by addition of a gelling agent.EFFECT: invention implementation allows to obtain a gel with a high stability of gel properties, transparency, stability of properties for up to 2 years, the use of which allows to reduce the clinical symptoms of hemorrhoids up to their complete elimination, anal fissure healing and relief of pain after hemorrhoidectomy.3 cl, 1 tbl
ethod for low-flow anesthesia based on sevoflurane with application of epiglottic i-gel duct // 2640016
FIELD: medicine.SUBSTANCE: induction into anesthesia is carried out by intravenous injection of 1% propofol solution at a dose of 1.5-2 mg/kg, up to 200 mg, and 0.005% fentanyl solution at a dose of 0.7-1 μg/kg. After reaching a sufficient depth of anesthesia with BIS 40-50 units, an epiglottic I-gel duct, a gastric tube through a special port on the duct are installed and the patient is transferred to lung ventilation in auxiliary modes: SIMV, PS; anesthesia is maintained by inhalation administration of sevoflurane at a dose of 1-2 volume percent with fresh gas flow of 0.8-1.2 l/min, via a semi-enclosed loop using a adsorber with soda lime; sevoflurane concentration is selected till a steady achievement of 0.6-0.8 MAK, analgesia is provided by intravenous administration of 0.005% solution of fentanyl; infusion therapy is carried out with physiological solution in a dose of 500-700 ml.EFFECT: adequate level of sedation and analgesia, reduced time of anesthesia, reduced drug burden on the body, and a lower risk of anesthesia complications.2 tbl
ethod for prevention of agitation syndrome in children with oncological pathology // 2635532
FIELD: medicine.SUBSTANCE: methodincludes single intranasal injection of dexmedetomidine at a dose of 2 mcg/kg prior to anesthesia with sevoflurane on a semi-open contour with maintained spontaneous breathing. Application of the invention makes it possible to achieve pre-anesthesia sedation level R3-R5 on the Ramsey scale without respiratory depression, development of analgesic effect.EFFECT: decrease in MAC of sevoflurane, prolongation of postnarvic sleep, a decrease in intracranial pressure, level of cerebral blood flow, and brain oxygen consumption.2 tbl, 2 ex
ethod for subdural analgesia as method for analgesia in first delivery period // 2633933
FIELD: medicine.SUBSTANCE: in the first delivery period, the puncture site is anesthetized with a solution of bupivacaine 0.5%. The subdural space is then punctured with a spinal needle at the level L3-4, L4-5 by median access, using an isobaric solution of bupivacaine 0.5% in doses of 0.8-1.2 ml as a local anesthetic. At that, the woman after the puncture remains lying on her side for 2-3 minutes, then turns to the opposite side for 2-3 minutes.EFFECT: decreased drug effect on the maternal and fetal organism, ensured rapid onset of qualitative and prolonged analgesia of the first delivery period.1 ex
ethod for anesthetic selection for anesthesiological support of neurovisualization in children with cns pathology // 2633906
FIELD: medicine.SUBSTANCE: examination and assessment of the patient's condition are performed before conducting a multispiral CT scan. The degree of risk of anesthesia is preliminarily determined by the criteria: state of consciousness, reaction to examination, presence of convulsive syndrome, allergic anamnesis, age. Each criterion is scored. The obtained estimates are summed up and at a value of 0-3 points, the degree of anesthesia risk is assessed as low, at a value of 4-7 points - as average, at a value of 8-12 points - as high. For patients with a high and moderate degree of anesthetic risk, 1% thiopental sodium is selected in a dose of 3-5 mg/kg once iv, for patients with a low risk, 1% propofol is selected in a 1:10 dilution at a dose of 1-2 mg/kg, once iv, with absolute contraindications to the use of propofol, a combination of 5% ketamine in a 1:10 dilution at a dose of 0.5-1 mg/kg once iv and 0.5% diazepam at a dose of 0.1 mg/kg once iv is selected.EFFECT: optimized approach to anesthetic selection, reduced number of complications, reduced time of awakening and staying in the hospital.3 ex
Application of lidocaine derivative with local anesthetic activity, for terminal anesthesia // 2628811
FIELD: medicine.SUBSTANCE: invention can be used for application of a lidocaine derivative - N-acetyl-L-glutamate 2-diethylamino-21,61-dimethyl phenylacetamide of the general formula (1) with local anesthetic activity, for terminal anesthesia.EFFECT: invention allows to reduce acute toxicity, increase the breadth of therapeutic action, increase the depth and duration of terminal local anesthesia without a local irritant effect compared to lidocaine.3 tbl, 3 ex
ethod for anesthetic maintenance during radical surgery for cancer patients // 2627289
FIELD: medicine.SUBSTANCE: after patient admission to the operating room dexmedetomidine administration starts at a dose of 0.6-0.8 mcg/kg/h. Then epidural space catheterization is perform lying on the side. Analgesic mixture administration starts at a rate of 5 ml/hour and continued throughout the operation. During denitrogenation, intravenous dexmedetomidine sedation is performed at an dose of 0.6-0.8 mcg/kg/hr, after repeated denitrogenation and transition to closed circuit, oxygen supply is stopped. The breathing bag is completely emptied, then Xe is fed rapidly, once filling the breathing bag, ventilation by pure Xe flow of 150-300 ml per minute is begun under the control of FiO2 to reduce the oxygen concentration in the breathing circuit to 40% and Xe concentration to 60%, and then oxygen is supplied at a dose of 4 ml/kg, maintaining the balance in the ratio of Xe:O2 60:40. Xe flow is reduced to 0-100 ml/min intravenous administering of dexmedetomidine is continued throughout the operation at a dose of 0.3-0.6 mcg/kg/hr. Prior to surgical wound suturing Xe supply is stopped. After surgery, anesthesia machine is converted to a semi-open circuit, oxygen flow is increased to 5 l/min, sodium sugammadex is introduced at the rate of used bromide rocuronium. The patient extubated, in the early postoperative period analgesic mixture administration is continued at a rate of 5 ml/hr and intravenous dexmedetomidine administration is continued at a dose of 0.3-0.6 mcg/kg/h under the control of sedation level and hemodynamics.EFFECT: method allows to obtain an efficient multimodal anesthetic protection, reduce xenon and narcotic analgesics consumption during extended and highly-traumatic cancer surgery.2 ex
ethod for epidural catheter installation for conduction of epidural analgesia in young mothers // 2626909
FIELD: medicine.SUBSTANCE: aseptic treatment and local anesthesia of the puncture site is performed, inserting the Tuohi needle No. 16-18G in the sagittal plane between spinous processes L2-L3. The mandrel is removed after sensation of a dip, a low-pressure syringe with saline is attached and the needle is moved till the loss of resistance for the saline in the syringe. The syringe is disconnected, then the catheter is inserted into the needle and pushed through the needle. A syringe with a 5-7 mm of saline is attaced to the outer end of the catheter. The catheter is slowly and continuously advanced in the cranial direction. Simultaneously, the connective tissue of the epidural space is infiltrated together with the epidural veins with saline, the catheter is placed at a depth of 4-5 cm.EFFECT: method allows to reduce the risk of epidural hematoma and unintentional injection of local anesthetic into the bloodstream for young mothers.1 cl
Agent for application anaesthesia with antiseptic, optical-keratoprotective properties and method for use thereof in ophthalmology // 2624901
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine and pharmacology, and can be used to produce an agent form of gel for application anaesthesia in ophthalmic surgeries. Agent contains following components, wt%: hydroxyethyl cellulose 1.2–1.8, glycerol 17–25, lidocaine hydrochloride 1.8–2.4, chlorhexidine dihydrochloride 0.03–0.07, water- balance up to 100. Also disclosed is a method of application anaesthesia in ophthalmic surgeries.EFFECT: group of inventions enables to produce an agent possessing antiseptic, optical-keratoprotective properties without preservatives, use of which enables to achieve complete anaesthesia with no complications.4 cl, 4 ex
Gel with oximethyluracyl, chlorohexidin and lidocaine for diagnostic and treatment endourethral procedures // 2624866
FIELD: medicine.SUBSTANCE: invention can be used for diagnostic and therapeutic procedures (cystoscopy, bladder catheterization, urethral expansion) as an anti-inflammatory antimicrobial anesthetic regeneration stimulating antioxidant antiviral agent with prolongation effect. The agent contains oxymethyluracyl, lidocaine and chlorhexidine bigluconate as active ingredients, contains polyethylene glycol 400, glycerin, lutrol F-127 and purified water as the gel basis at a certain ratio of components.EFFECT: creation of a new therapeutic and diagnostic antimicrobial anesthetic anti-inflammatory regenerative antioxidant antiviral agent, with good fixation, spreadability, pronounced and prolonged action, convenient in application.2 tbl, 5 ex
ethod of prophylaxis of post-traumotomic pain syndrome in oncosurgery // 2619212
FIELD: medicine.SUBSTANCE: for the prevention of post-thoracotomy pain syndrome (hereinafter - PTPS) in oncosurgery a day before the surgery, anticonvulsant pregabalin is administered orally 75 mg 2 times/day and 75 mg 2 hours before the operation. Then, an epidural catheter is performed on the operating table, through which a three-component mixture is infused throughout the operation: ropivacaine 3 mg/ml+fentanyl 4 mcg/ml+epinephrine 2 mcg/ml at a rate of 5-15 ml/h. Induction of anesthesia is intravenously: fentanyl 0.00004±0.00002 mg/kg, ketamine 0.29±0.13 mg, propofol 0.56±0.31 mg/kg, rocuronium bromide 0.68±0.14 mg/kg. Maintenance of anesthesia: sevoflurane inhalation 0.6-1 MAK in an oxygen-air mixture (FiO2 0.3-0.8), fentanyl 0.00004±0.00002 mg/kg/h, ketamine 0.0013±0.0002 mg/kg/hour. 40 minutes before the end of the operation, nefopam is administered with 20 mg IM. In the postoperative period, infusion is performed in the epidural space: ropivacaine 2 mg/ml+fentanyl 4 mcg/ml+epinephrine 2 mcg/ml, injection rate 4-6 ml/h for 2 days. Then, the mixture reduces the concentration of ropivacaine to 0.2% and continues infusion to 5-7 days, at a rate of 4-6 ml/h. At occurrence of the first complaints on painful sensations prescribe nefopam of 20 mg im/m and continue its appointment in a dose of 20 mg 2 times a day for 5 days and lornoxicam 8 mg intravenously - 2 times/day and pregabalin 75 mg orally - 2 times/day for 5 days. In case of ineffectiveness of this therapy, morphine is prescribed 10 mg IM.EFFECT: invention allows to reduce the frequency of development of acute PTPS, its intensity, to reduce the postoperative need for opioid analgesics and to reduce the frequency of development of chronic PTPS.2 ex
ethod for postanesthetic excitation prevention for children with cancer // 2617204
FIELD: medicine.SUBSTANCE: standard mask inhalation anesthesia with sevoflurane with preserved spontaneous breathing is performed. At the same time, high-risk postanesthetic excitation is identified for children from 1 to 7 years with rapid awakening after anesthesia and presence of pain impulses in history at the stage of preliminary examination, before the operation by interviewing parents with answer yes or no answer selection. Childbirth (rapid, prolonged), childbirth using various kinds of maternity, regurgitation, not related to food intake, chin tremor, throwing the head back, difficulty in falling asleep, restless, short-term, superficial sleep, sleeptalking, sleepwalking, bedwetting, affective-respiratory convulsions, meteosensitivity, skin mottling, akro-, periorbital and perioral cyanosis, febrile convulsions, logoneurosis, obsessive-compulsive movements, headaches, tendency to constipation, attention deficit, expressed red or white dermographism, general and local hyperhidrosis, thermoregulatory dysfunction, retarded rate of mental and speech and motor development, presence of fear in a child, incoordination of movements. Upon reception of affirmative answers to 2 or more questions, the child is identified as a patient with high risk of postanesthetic excitation syndrome development. At the end of anesthesia, the breathing circuit of such patients is filled with pure oxygen and inhalation of 100% oxygen is continued via a face mask for 8 minutes. At that, 1% propofol at the rate of 1-1.5 mg/kg, dissolved in 0.9% sodium chloride solution in the ratio 1:5 is administered slowly intravenously.EFFECT: method prevents excitation after inhalational anesthesia with sevoflurane when performing short painful manipulations in children with cancer due to reduced intracranial pressure, elongated phase of drug-induced sleep, achieved sympatho-vagal balance, improved tissue oxygen saturation and reduced pain intensity.2 tbl, 2 ex

Aminoindane compounds and use thereof in treating pain // 2612959
FIELD: chemistry.SUBSTANCE: invention relates to novel aminoindane compounds of formulae (I) or (II): , where: A is phenyl or a monocyclic aromatic 5- or 6-member ring containing 1 or 2 heteroatoms selected from N and S; R1 and R4 are independently C1-C6 alkyl or CH2CH2OH; or R1 and R4 are combined to form a 4-6-membered carbocyclic or saturated 5- or 6-member monocyclic group containing one additional ring heteroatom, such as O; R2 is independently selected from a group consisting of halogen; R3 is independently selected from a group consisting of halogen and C1-C-6 alkyl; or q equals 2, and two R3 groups are bonded to form a saturated 5- or 6-member monocyclic group containing 1–2 oxygen atoms; m is ranges from 1 to 3; n ranges from 1 to 3; p ranges from 0 to 2; q ranges from 0 to 2; and X- is a halogen, trifluoroacetate, sulphate, etc, as well as methods of producing and using said compounds. Methods involve administering a compound of formula (I) or (II) and a TRPV1 receptor activator.EFFECT: said compounds can find application in treating pain and/or itching.14 cl, 8 tbl, 11 dwg, 59 ex
ethod of anesthesia for transrectal prostate biopsy // 2608604
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to oncourology. Before introduction of ultrasonographic probe into rectum in tessellated space between fascia Denonvile and prostate capsule 20 ml of 0.5 % solution of novocaine is introduced with standard needle of disposable syringe at distance of thumb width from anus at 10–12 hours of conditional clock face to the right and at 12–2 hours of conditional clock face to the left.EFFECT: method allows to safe and quickly relieve pain for transrectal prostate biopsy,without expensive consumables, including patients with chronic diseases of rectum and anal canal.1 cl, 2 tbl, 2 ex

Agent for treating pyoinflammatory processes in soft tissues and mucous membranes // 2601897
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to agents possessing antimicrobial, sorption, analgesic and wound healing action on local pyoinflammatory processes in soft tissues and mucous membranes, used in surgery, dermatology, obstetrics and gynecology, otorhinolaryngology. Declared agent for treating pyoinflammatory processes in soft tissues and mucous membranes is a film and contains as therapeutic ingredients antiseptic chlorhexidine bigluconate 0.05 % and stimulator of regeneration methyluracil, comprises the base polyethylene oxide with molecular weight 400 (PEO-400) and carboxymethyl cellulose sodium salt (Na-CMC), also as a therapeutic component-metronidazole, as anaesthetic contains lidocaine hydrochloride, as a stabilizer - glycerine in the amounts specified in the patent claim.EFFECT: technical effect consists in creation of effective remedy in the form of film, possessing antimicrobial, sorption, analgesic and wound healing action.1 cl, 3 tbl
ethod of high spinal anaesthesia in operations on top floor of abdominal cavity // 2599044
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to anaesthesiology. In a patient side position performed is a middle or a paramedian access. After local anaesthesia puncture is performed at the level of LIV-LV with a needle of diameter 25 G and less. Introduced into the subarachnoid space are 40 mg of 2 % lidocaine solution, herewith the edge of the needle during puncture of the dura mater and verification of the subarachnoid space is directed sagittally right or left. Then introduced is an isobaric marcaine solution in the total dose of 15-20 mg, while placing the needle edge maximum cranially, herewith the time of a single-stage introduction of marcaine with bubbling liquor in the amount of up to 5-10 ml is equal to 1-2 minutes. Further regulation of the block development and control over the block is done by inclination of the head end of the table to 45-60° and controlled by noninvasive measurement of blood pressure and heart rate.EFFECT: method enables to combine positive properties of subarachnoid anaesthesia meaning simplified, fast start, prolonged analgetic and myorelaxing effect, besides, softer and easier postoperative period, faster postoperative rehabilitation of patients, no need for a long myoplegia (intraoperative and postoperative), no period of postanesthetic depression, no need for an artificial pulmonary ventilation.1 cl, 3 ex

ethod for block anaesthesia accompanying intranasal surgical correction // 2597155
FIELD: medicine.SUBSTANCE: by administering Ultracain D-S forte 1:100000 solution into specific points of face, palate and nose.EFFECT: invention enables providing an adequate anaesthesia and blocking the innervation of external nose and adjoining anatomical regions, as well as preventing undesired tissue infiltration at the site of planned operation.2 cl, 6 dwg, 2 ex
ethod of pelvic diseases therapeutic block in animals and offering obstetric aid during pathological delivery // 2596725
FIELD: veterinary science.SUBSTANCE: invention refers to veterinary science and concerns pelvic diseases therapeutic blockade in animals or offering obstetric aid during pathological delivery. Method involves determining needle stick point and introduction of 0.25-0.5 % novocaine. Needle is stuck to right or left side along inner edge of iliac bone to its stop at inner surface of iliac bone wing. At that, end of needle is pulled up and novocaine solution is introduced in amount of 0.5 ml per 1 kg of animal body weight. For 0.5 ml of introduced solution added 0.1 mg of dexamethasone, 0.1 ml of polyglucin and 10 mg of ceftriaxone or gentamycin. Similarly acting on opposite side of pelvis.EFFECT: method provides fast and stable elimination of pain and inflammatory reaction.1 cl, 4 ex

ethod for producing a pharmaceutical formulation of rocuronium bromide in the form of a stable lyophilisate and pharmaceutical composition obtained using said method // 2594062
FIELD: pharmaceutics. SUBSTANCE: present invention relates to pharmaceutical industry and to a method for producing a pharmaceutical formulation of rocuronium bromide in the form of a stable lyophilisate for injection or infusion. Method includes placing the solution rocuronium bromide in ampoules or bottles in a sublimation chamber, where the solution is frozen to (-41)-(-49)°C at the rate (-12)-(-13) deg/h during 7-9 hours, held for 6-9 hours, then the ampoules (bottles) are heated at a rate of 7-10 deg/h during 7-9 % to 20-25 °C and kept at this temperature for 5-9 hours. Pharmaceutical formulation includes rocuronium bromide as an active ingredient, sodium chloride or potassium chloride, acid to bring pH to 3.8-4.8 and water for injections. EFFECT: pharmaceutical formulation storage life increases up to 5 years. 2 cl, 3 tbl, 1 ex
ethod of blocking nerves of pelvic plexus in dogs, cats and fur animals of dog family and carnivores // 2592024
FIELD: veterinary science. SUBSTANCE: laparotomy is performed. Method includes adding novocaine or lidocaine by means of a syringe needle in a loose connective tissue between visceral fascia of pelvic fascia, wall of ampoule-like rectal expansion at an acute angle to medial surface of visceral leaf of pelvic fascia along ampoule-like expansion of rectum at depth from 3 to 10 cm with both one and other side of body. Small and medium breeds of dogs, cats and fur animals of dog and carnivores are administered from 3 to 5 ml of 0.5 % novocaine or lidocaine. Large and giant breeds dogs are administered 5 to 10 ml 1 % novocaine or lidocaine. EFFECT: method enables to reduce intraoperative injuries, toxic effect of used anaesthetics. 1 cl
ethod of anesthesia on an outpatient basis in patients dental profile // 2591638
FIELD: medicine.SUBSTANCE: prior to surgery by intravenous infusion using the infusion device controlled within 10 minutes of dexmedetomidine injected to a concentration of 4.0 mcg/ml in a dose of 1.0 mcg/kg of patient body weight, then the rate of infusion of the drug was reduced to 1.0 mcg/kg/h. Spend local infiltration anesthesia of the surgical solution of articaine hydrochloride 40.0 mg/ml. Next, a surgical intervention, upon completion of dexmedetomidine infusion was stopped. At the same time, before, during and after the induction of anesthesia and surgery, as well as to the full recovery of consciousness of the patient is carried out continuously monitor observation of blood pressure, pulse, oxygen saturation, respiratory rate, ECG.EFFECT: method allows you to improve the quality of anesthesia on an outpatient basis in patients dental profile.1 cl, 1 ex

ethod for prevention of atrial fibrillation in open lung surgeries of oncology diseases // 2574187
FIELD: medicine.SUBSTANCE: whole surgical intervention involves the continuous infusion of a mix of 0.3% Ropivacaine with Fentanyl 4 mcg/ml and adrenalin 2 mcg/ml at the saturation rate of 8-12 ml/h to be reduced to 4-6 ml/h. The postoperative period involves continuing the infusion of the mix of 0.2% Ropivacaine with Fentanyl 2 mcg/ml and adrenalin 2 mcg/ml. The period of 5-7 days involves the infusion of 0.2% Ropivacaine at the average rate of 4-8 ml/h. With controlling the cardiac rate, from the first postoperative day, the high-selectivity β-adrenoceptor blocking agent bisoprolol is prescribed in a dose of 2.5-10 mg/day and ascorbic acid 250 mg/day.EFFECT: method provides reducing the probability of postoperative atrial fibrillation, a postoperative need in anaesthetics used for hypnotic and antinociceptive purposes, and also an intraoperative and postoperative need in opioid analgesics during the early postoperative period.2 tbl, 2 ex

Anaesthetic composition // 2574022
FIELD: chemistry.SUBSTANCE: invention relates to medicine and represents anaesthetic composition, which contains neuroactive steroidal anaesthetic, composed with cyclodextrin, where neuroactive steroidal anaesthetic is selected from the group, consisting of alphadolone, alphaxalone and pregnanolone. Cyclodextrin represents (7) sulphobutyl ether of beta-cyclodextrin. Molar ratio of steroidal anaesthetic to cyclodextrin is within the interval from 1:1.6 to 1:2.5, except alphadolone, where it constitutes from 1:2 to 1:2.5. Invention also relates to methods for induction of anaesthesia and sedative effect by means of composition.EFFECT: low toxicity and reduced content of sulphoalkyl ether of beta-cyclodextrin.7 cl, 11 ex, 7 tbl, 12 dwg
ethod of personalised intraoperative contact local hyperthermia for treatment of locally advanced malignant tumours // 2565810
FIELD: medicine.SUBSTANCE: heating of bed of ablated or resected tumour is performed with application of intraoperatively made individual tissue-equivalent applicator copying tumour bed shape. Applicator is made from self-polymerising material, in which ferromagnetic filler is introduced at stage of manufacturing. In the process of manufacturing surface of tissue-equivalent applicator is covered with protective film from self-absorbable polymer material. Antibiotics, anti-tumour preparations and anaesthetics are preliminarily added into polymer base of protective film.EFFECT: elimination of possibility of direct contact of ferromagnetic filler with tissues, located in operation field zone, intensification of dissolution of active substances, reduction of number of pyoinflammatory complications, reduction of tumour recurrences, including due to creation of high concentration of preparations in operation field zone and in bed of ablated tumour.2 cl, 1 ex

Pharmaceutical composition with analgesic activity in injection form (versions) // 2563211
FIELD: medicine, pharmaceutics.SUBSTANCE: pharmaceutical composition with kappa-opioid agonistic activity, demonstrating an analgesic effect in accordance with the first version contains 9-(2-morpholinoethyl)-2-(4-fluorophenyl)imidazo[1,2-α]benzimidazole dihydrochloride as an active component, and an isotonicity corrigent, selected from salts of organic and inorganic acids, polyols, amino acids, as auxiliary substances. The composition can additionally contain a co-solvent, a corrigent of the solution pH, a cryoprotector, and an antioxidant. In accordance with the second version the pharmaceutical composition contains 9-(2-morpholinoethyl)-2-(4-fluorophenyl)imidazo[1,2-α]benzimidazole dihydrochloride as an active component, and a co-solvent, selected from ethyl alcohol, glycerol, propylene glycol, benzylbenzoate, benzyl alcohol, ethyloleate and fatty oils, including olive oil and peach oil as auxiliary substances. The composition can additionally contain an isotonicity corrigent, a corrigent of the solution pH, a cryoprotector, and an antioxidant.EFFECT: invention provides the pharmaceutical composition in an injection form with kappa-opioid agonistic activity without narcogenic potential, demonstrating the fast relief of pain syndrome.12 cl, 5 dwg, 3 tbl, 4 ex

Etomidate analogues which do not inhibit synthesis of adrenocorticosteroids // 2559888
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to compounds of formula , where R1 represents L1C(O)OT; R2 represents C1-C10alkyl; n is equal 0; R4 and R5 independently represent H; L1 represents bond; T represents ethyl, propyl, isobutyl, n-butyl; and its pharmaceutically acceptable salts, stereoisomeric mixtures and enanthiomers.EFFECT: compounds provide anaesthetic action in mammals.8 cl, 8 dwg, 7 ex
ethod for anaesthesia in extended partial mastectomy with axillary-subcapular lymphadenectomy in senior patients // 2559278
FIELD: medicine.SUBSTANCE: after a surgical site has been treated from three points at a breast base: superior internal and superior external, superior and inferior external, inferior external and inferior internal quadrants junctions, the skin is infiltrated with 0.25% Novocaine solution. Further, a long needle is used to inject 0.25% Novocaine 40 ml from the marked points into the retromammary space on either side. Besides, from the fourth point: axillary subcutaneous fat is infiltrated along a border of a greater pectoral muscle with smoothly changing the needle direction. That is followed by the infiltration anaesthesia of the skin and underlying tissues along the outline of the quadrant to be removed. What is also required is a Novocaine block of separated thoracodorsal nerve and long thoracic nerve.EFFECT: enabling the lymphadenectomy with no general anaesthesia required, which is ensured by the infiltration anaesthesia combined the retromammary Novocaine block and the additional anaesthesia of the thoracodorsal nerve and long thoracic nerve.1 ex
ethod for anaesthetising patients with chronic pain syndrome undergoing cyclophotocoagulation surgery // 2556792
FIELD: medicine.SUBSTANCE: anaesthetising patients with chronic pain syndrome undergoing a cyclophotocoagulation surgery involves the intravenous administration of the hormonal preparation dexamethasone in a dose of no more than 8 mg followed by the anxiolytic droperidol in a dose of no more than 2.5 mg 5 minutes prior to the operation before the peribulbar anaesthesia. A peripheral block in the form of the peribulbar anaesthesia involving administration of no more than 6 ml of a local anaesthetic follows. At the moment the surgical procedure starts, benzodiazepin, e.g. diazepam, is administered in a dose of no more than 5 mg.EFFECT: achieving adequate anaesthesia in the given category of patients by blocking all the links of a pathological pain chain.1 ex
ethod for combined prolonged anaesthesia assisting hip replacement // 2555121
FIELD: medicine.SUBSTANCE: dexamethasone 8 mg and ketoprofen 100 mg is administered intravenously once prior to the operation. A lumbar plexus is blocked in a combination with a parasacral block and inserting perineural catheters to administer weak 0.2% Ropivacaine, local anaesthetic 20 ml. Paracetamol 1,000 mg is administered intravenously 30 minute before the operation is completed. After the operation is completed, the perineural catheter of the lumbar plexus is used to infuse 0.2% Ropivacaine 300 ml at 6-8 ml/hour for 4-5 days. Ketoprofen 100 mg is administered intramuscularly twice a day for 3 days. Through the perineural catheter of the parasacral plexus, 0.2% Ropivacaine 10 ml is administered twice every 12 hours.EFFECT: method provides the adequate anaesthesia in the given category of patients by having an effect on primary pain components, as well as ensures the continuous and prolonged anaesthesia both intra-, and postoperatively, prevents the stable and chronic pain syndrome and the motor block of the extremities, reduces a rate of toxic complications.1 ex

ethod for managing neuropathic pain // 2554494
FIELD: medicine.SUBSTANCE: invention refers to chemical-pharmaceutical industry and represents a pain control formulation containing 4 wt % to 10 wt % of Lidocaine and 4 wt % to 10 wt % of Tetracaine, 10 wt % to 40 wt % of polyvinyl alcohol, water and sorbitan monostearate (Span 60) as an emulsifier, wherein water/PVA mass ratio makes more than 2.5, wherein the formulation provides the transdermal delivery of Lidocaine and Tetracaine, and wherein the delivery is terminated or considerably slows down when water evaporates completely, and wherein the formulation possess an initial viscosity from approximately 28,000 centipoise to approximately 828,000 centipoise, and shows a after 3 freeze-thaw cycles at least 2 times as much as the initial viscosity; the freeze-thaw cycle is determined by placing the formulation into the environment of temperature -18°C to -22°C for the time period of 48 hours and thawing the formulation at room temperature (approximately 25°C) for the time period of 48 hours.EFFECT: invention provides the improved long-term storage of the compositions.16 cl, 9 ex, 7 tbl, 2 dwg
ethod for retrobulbar anaesthesia in oncological eye diseases with use of b-ray applicator // 2553193
FIELD: medicine.SUBSTANCE: catheter is inserted into the retrobulbar space and used to introduce 2% lidocaine 1 ml and 0.5% marcaine 1 ml 15-20 minutes before applicator anchoring. The catheter is left in the retrobulbar space for 1-7 days. 10-15 minutes before removing the applicator, 2% lidocaine 0.5-1 ml and 0.5% marcaine 0.5-1 ml are introduced through the catheter. 4-6 hours after anchoring and removing the applicator, 2% lidocaine 1 ml and 0.5% marcaine 1 ml are introduced respectively additionally.EFFECT: achieving adequate and prolonged anaesthesia in a combination with reducing a risk of a retrobulbar haematoma, eyeball puncture and visual nerve damage by eliminating the retrobulbar space re-puncture.2 ex

ethod of anaesthetics and prevention of inflammatory complications after median sternotomy // 2553178
FIELD: medicine.SUBSTANCE: after performing median sternotomy pericardial and mediastinal drainages are installed and sternum is sutured. After suturing sternum for length of its entire front surface, catheter is installed through skin counterpuncture, with 1.0-2.0 cm indent from lower wound edge. proximal end of catheter is fixed to subcutaneous-adipose cellular tissue with absorbable suture material, and distal part of catheter with cannula is fixed by suturing to skin with non-absorbable suture material. Local anaesthetic is introduced through installed catheter every 6 hours, with antibiotic being introduced every 8 hours. Introduction of medications is performed for 3-5 days.EFFECT: method provides effective anaesthetics with simultaneous drainage of front sternum surface and skin wound due to introduction of anaesthetics and antibiotics via catheter into said zone, which additionally reduces quantity of exudative inflammatory complications in post-operative period.2 dwg, 1 ex
ethod for preanaesthetic medication preceding gynaecological surgeries under general anaesthesia // 2549474
FIELD: medicine.SUBSTANCE: preanaesthetic medication preceding gynaecological surgeries under general anaesthesia is ensured by prescribing diazepam 10mg, nefopam 10mg and ketoprofen 100mg intramuscularly 30-40 min before the surgery.EFFECT: method enables reaching the sedative and analgesic effect of the preanaesthetic medication by the complementary action of preparations with no undesired side effects, requiring no time consumption and expensive equipment.3 tbl, 2 ex

ethod for spinal anaesthesia in pregnant women suffering concomitant cardiovascular pathology // 2548510
FIELD: medicine.SUBSTANCE: spinal anaesthesia is followed by catheterisation of an epidural space at the level of L1-L2. The spinal anaesthesia is performed at the level of L4-L5 by administering 0.5% bupivacaine. Bupivacaine is administered in a dose of 5-6 mg if the pregnant woman's height is less than 165 cm, and the dose is 6-7 mg if the pregnant woman is from 165 to 175 cm high. After the local anaesthetic is administered into the epidural space, normal saline is introduced. If the intra-abdominal pressure is ≤16 cm H2O, normal saline 15 ml is administered; if the intra-abdominal pressure is 17-21 cm H2O, an amount of normal saline is 10 ml, whereas the intra-abdominal pressure of 22-28 cm H2O requires an amount of 5 ml.EFFECT: performing the effective spinal anaesthesia combined with reducing a probability of hypertension by dilating the epidural space preliminary in accordance with the intra-abdominal pressure.1 tbl, 1 dwg, 2 ex

Pharmaceutical composition in solid form with analgesic activity // 2545861
FIELD: chemistry.SUBSTANCE: as active component pharmaceutical composition contains dihydrochloride of 9-(2-morpholine ethyl)-2-(4-fluorophenyl)imidazo[1,2-α]benzimidasol, and as additional substances - fillers, binding, sliding and film coatings, in quantities, given in the invention formula. Composition can be made in form of solid medication form, mainly in form of tablets and capsules.EFFECT: obtained solid medication forms satisfy the requirements of the State Pharmacopoeia.7 cl, 2 dwg, 3 tbl, 14 ex
Percutaneously absorbable preparation // 2543639
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to a percutaneously absorbable layer having a base and an adhesive layer which is placed on the base and which comprises an adhesive agent and a therapeutic ingredient. The adhesive agent contains a mixture of resins containing 100 portions by weight of an acrylic copolymer (A) and 0.1 to 30 portions by weight of an acrylic copolymer (B) or 0.05 to 2 portions by weight of a low-molecular polyamine compound having at least two amino groups in one molecule and non-polymerising with a polymer or an oligomer formed. The adhesive layer additionally contains an organic acid. The acrylic copolymer (A) represents an acrylic copolymer, which contains acrylic ester of (meth)acrylic acid as a main monomer ingredient and contains 3 to 45 wt % of diacetone acrylamide as a target monomer ingredient, but free from a free carboxylic group. The acrylic copolymer (B) represents an acrylic copolymer, which contains acrylic ester of (meth)acrylic acid as a main monomer ingredient and contains a primary amino group and/or carboxyhydrazidase group on side chains, but free from a free carboxylic group.EFFECT: reducing the aging period of the adhesive layer considerably.7 cl, 8 tbl, 39 ex
Antiseptic and analgesic therapeutic agent in form of gel for processing and lubricating catheters used in examining and treating urogenital system // 2540921
FIELD: medicine.SUBSTANCE: therapeutic agent contains hypromellose, boric acid and a consistency base; it additionally contains anesthesin or lidocaine as an analgesic in an amount of 0.00001-0.5 g.EFFECT: fixing a lubricating agent on the catheter enabling preventing mucosal injuries accompanying a drainage procedure, and eliminating side effects.3 cl, 6 ex

ethod for preventing pain and psychoemotional responses in endovascular x-ray surgeries // 2540905
FIELD: medicine.SUBSTANCE: at the initial stage of the intraoperative period, immediately before the local anaesthesia and the femoral artery puncture, ketorolac tromethamine is administered intravenously as an analgesic, and propofol as a sedative agent. Ketorolac tromethamine is administered in a dose of 15-75 mg, while propofol is administered in a dose of 50-250 mg.EFFECT: method prevents developing pain and psychoemotional responses caused by the given interventions, including postoperatively by the fast development of the adequate analgesic effect accompanied by the controlled sedation level.1 tbl, 10 ex

Etomidate analogues with improved pharmacokinetic and pharmacodynamic properties // 2540116
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to organic chemistry, namely to benzimidazole derivatives of general formula (I) and to their pharmaceutically acceptable salts, mixed stereoisomers and enantiomers, wherein R1 is L1C(O)OL2C(O)OT; R2 is unsubstituted C1-C10alkyl; L1 is a bond; L2 is unsubstituted C2-C10alkylene; T is C1-C10alkyl. Also, the invention refers to a pharmaceutical composition of the compound of formula (I) and a method of anaesthetising on the basis of using the compound of formula (I).EFFECT: there are prepared new imidazole derivatives effective as an anaesthetising agent.15 cl, 9 dwg, 15 ex
ethod for prolonging anterior chamber anaesthesia and pupil dilatation experimentally // 2540007
FIELD: medicine.SUBSTANCE: anterior chamber anaesthesia and pupil dilatation accompanying anterior eye segment surgeries experimentally involve a preoperative administration of a composition in an amount of 0.1-0.2 ml representing 0.005% 1-(3-pyrrolidinopropyl)-2-phenylimidazo[1,2-a]benzimidazole dihydrochloride into the anterior eye segment. The composition is prepared in 1% viscoelastic solution, visiton PEG.EFFECT: prolonging anaesthetic effect and pupil dilatation with no mydriatics used.2 ex
ethod of intramesovarian blockade of ovarian and cranial uterine nerves in dogs and fur-bearing animals of canine family // 2539425
FIELD: veterinary medicine.SUBSTANCE: intramesovarian blockade of ovarian and cranial uterine nerves is carried out by laparotomy and administration in the mesovarium of 0.5-1% solution of novocaine or lidocaine. Blockade is carried out by inserting the needle of the syringe into the mesovarium in the vicinity of the ovarian bursa and uterine horn at an acute angle to the surface of the ovarian mesenterium to a depth of 3-4 cm. At that 3 ml of anaesthetic is administered to small breeds of dogs and fur-bearing animals, and from 3 to 9 ml of anaesthetic is administered to large and giant breeds of dogs as from one and from the opposite side of the body.EFFECT: effective implementation of intramesovarian blockade by taking into account the anatomical and the breed features of the animal category.1 tbl

ethod for novocaine block // 2536283
FIELD: medicine.SUBSTANCE: patient is laid on his/her side opposite a block region. A guide mark is a vertical line in a projection of Petit's triangle from the twelfth rib to a wing of ilium. A needle is pricked into the skin on the vertical line at 1.5-2.5cm above the wing of ilium. 0.25% Novocaine is administered in layers into the skin and subcutaneous fat. The needle is advanced into the lumbar region from back to front in the medial direction along the lateral edge of broadest muscle of back at 6-8cm. Novocaine 120ml is administered into the lower order of the lumboiliac fossa formed in this region.EFFECT: effective and safe pain management in the given category of patients by providing the required Novocaine concentration in the retroperitoneal space.1 dwg, 1 ex

Enantiomers of spiro-oxindole compounds and using them as therapeutic agents // 2535667
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to a new compound, namely to (S)-enantiomer of 1'-{[5-(trifluoromethyl)furan-2-yl]methyl}spiro[furo[2,3-f][1,3]benzodioxol-7,3'-indole]-2'(1'H)-one of formula (I), and a method for preparing it which is effective for treating diseases and conditions, such as pain, an intensity of which can be reduced or relieved by modulating potential-dependent sodium channel gatings.EFFECT: invention refers to the pharmaceutical composition of the above compound, methods of treating and a method of relieving an ion flux through the potassium channel gating in a cell.10 cl, 5 tbl, 6 dwg, 11 ex

icrocolloidal solution of propofol for anaesthesia // 2535001
FIELD: biotechnology.SUBSTANCE: aqueous composition for anaesthesia is proposed, which comprises propofol as an active agent, the PEG-660-12-hydroxystearate as a solubiliser, benzyl alcohol, or chloroethanol or parabens as preservative, the tocopherol and arginine or glycine at a specific content of components wt %. The GABA agonists can be additionally added to the composition, e.g. aminophenyl-butyric acid, local anesthetics such as lidocaine, alpha-2-adrenoceptor agonists such as xylazine. The method is proposed for implementing anaesthesia comprising administering to a patient of an effective amount of the claimed composition.EFFECT: invention provides low toxicity of dosage form and high efficiency.5 cl, 3 tbl, 1 ex

ethod for assessing limb distal circulation reserves // 2530764
FIELD: medicine.SUBSTANCE: radionuclide indicator is administered to record the dynamics of its distribution in limb tissues by a radionuclide method. The examination is performed at rest and during a load test. The load test represents an epidural block by gradual administration of bupivacaine 25-30 mg between L2-L3 vertebrae for 5-7 minutes. That is followed by measuring a blood flow as a percentage of its value to the same level in an analogous segment of a collateral limb.EFFECT: qualitative assessment of the circulation reserve in various categories of patients, including disabled ones by inhibiting sympathetic and minimally sensory activity with maintaining the patients' motor activity.2 dwg, 2 ex

ethod for preperitoneal block following median postoperative ventral hernioplasty // 2529412
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to abdominal surgery and anaesthesiology, and can be used where it is necessary to anaesthetise after the prosthetic hernioplasty for median postoperative ventral hernias. That is ensured by placing an endoprosthesis under the aponeurosis, a polyvinylchloride catheter is placed into the formed spaced around the periphery of a postoperative wound in the form of an oval above the endoprosthesis plane at 2.5-3 cm from its edges. Along its full length, the catheter has multiple side holes. Single openings are created in a projection of a lower corner of the wound, and the catheter ends are brought out onto the skin. An inlet of the catheter is attached to a local anaesthetic dosage device by means of a cannula. That is followed by a controlled prolonged irrigation with 2.5% Ropivacaine 20 ml every 6-8 hours during 2-3 days.EFFECT: method enables the adequate postoperative anaesthesia, as well as the length of the postoperative intestinal distention by providing the uniform controlled administration of the local anaesthesia solution.7 dwg, 1 ex
ethod for providing higher efficacy and safety of ultrafast opioid detoxification // 2524421
FIELD: medicine.SUBSTANCE: what is involved is infusion therapy with crystalloid solutions at 15 ml/kg of a patient's body weight. That is followed by puncturing and catheterising an epidural space at the level of ThVII-ThVIII according to the standard practice and introducing a test dose of 2% lidocaine 3 ml. If observing no signs of intrathecal introduction of local anaesthetics 10 minutes later, a basic dose containing 0.75-1% naropin 10 ml or 0.25-0.5% marcaine 10 ml and clofelin 3-5 mcg/kg is introduced. Total intravenous anaesthesia follows 20 minutes after pre-medication with atropine 0.01 mg/kg, 1% diphenylhydramine 1 ml and relanium 10 mg and urethral catheterisation. A narcosis is induced with propofol in a dose of 2 mg/kg. Anaesthesia is maintained with propofol 2-4 mg/kg·h. After that, within the first hour following the detoxification, naloxone 12 mg is introduced intravenously; a naloxone measurement rate is supposed to make 0.8 mg/h for 4-5 following hours of general anaesthesia. The repeated introduction of 0.75-1% naropin 6 ml or 0.25-0.5% marcaine 6 ml and clofelin 2-3 mcg/kg into the epidural space is performed 90 minutes later. After the procedure is terminated, and the patient recovers, prolonged epidural analgesia is conducted by introducing 0.2% naropin 10 ml and clofelin 1 mcg/kg into the epidural space every 4 hours for 24-48 hours.EFFECT: method provides safety of ultrafast opioid detoxification and prolongs the remission in the given category of patients.1 ex
ethod for measuring sympathetic block in epidural anaesthesia (analgesia) // 2521837
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to anaesthesiology and resuscitation, and may be used in epidural anaesthesia. That is ensured by administering slowly intravenously a basic dose of the local anaesthetic: 0.2-1% naropin or 0.2-0.5% marcaine, or 1-2% lidocaine; 1% Sol. Nicotini acidi 1% - 0.5-1 ml into the epidural space 10-20 minutes later. After 5-10 minutes, nicotine test results are visually evaluated by determining a clear interface of skin colour - hyperemic and normal - along an axillary line from both sides. The normal skin interface corresponds to the sympathetic block.EFFECT: method provides higher accuracy and simplification of measuring the sympathetic block.1 ex

ethod of anaesthesia after herniorrhaphy by inguinal access in case of inguinal hernias // 2521836
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to anaesthesiology and surgery, and can be used in case of anaesthesia necessity in patients after herniorrhaphy with inguinal access in case of inguinal hernias. For this purpose after the main stage of operation - hernioplasty, before suturing of the aponeurosis of the external oblique abdominal muscle, through subcutaneous adipose cellular tissue a puncture of 1 cm more medially and 1 cm higher than the anterior-superior iliac spine is made. A multiperforated catheter is introduced through the puncture under finger and visual control in such a way that its distal end is near the pubic tubercle. The catheter is placed under the aponeurosis of the external oblique abdominal muscle in the inguinal canal above and parallel to the spermatic cord in men or the round ligament of uterus in women. All the side holes of the catheter must be located in the subaponeurotic space. The first 48 hours of the post-operation period the local anaesthetic is continuously introduced by drop infusion at a rate of 2-4 ml/h or by bolus introduction in a dose of 10 ml each 4-6 hours through the catheter. After 48 hours the catheter is removed.EFFECT: method provides adequate anaesthesia in the said category of patients in the post-operation period without application of additional anaesthetic preparations due to blockade of ilioinguinal, ilioceliac and hollow branch of genitofemoral nerves.2 dwg, 2 ex

ethods for reducing pain and drug delivery devices // 2513219
FIELD: medicine.SUBSTANCE: group of inventions refers to medicine, and may be used in treating the patients suffering headaches and facial pains. There are presented versions of a drug delivery device comprising an injector a first end of which is left outside patient's nasal passages. Another end of the injector comprises one or more holes for spraying a drug upwards, and/or to the side, and/or to the front towards a sphenopalatine ganglion, an input device interacting with a patient's nostril and comprising a canal for receiving the injector. Additionally, the device can comprise a handle connected to the input device and provided for receiving the canal of the input device. The injector can move between a storage position before the interaction, and an interaction position related to the interaction. There are also presented versions of the method of using the above device that involve introducing the injector through the nasal passage into median and/or posterior and/or inferior region in relation to the patient's sphenopalatine ganglion, and spraying the drug.EFFECT: group of inventions provides faster and more effective headache and facial pain relief by safe and accurate drug delivery of the therapeutic substances blocking the sphenopalatine ganglion.49 cl, 4 dwg, 30 ex